MA-EVERBRIDGE
6.10.2020 22:12:09 CEST | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced additional top-tier Fortune 50 C-level executives, government officials and healthcare experts who have joined as speakers for its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006006062/en/
The latest speakers to join the Symposium include: retired Ford Motor Company Chief Executive Officer Jim Hackett, IBM President Jim Whitehurst, Mayo Clinic Platform Chief Medical Officer Clark C. Otley, M.D., Kaiser Permanente Associate Executive Director Stephen Parodi, MD, Los Angeles World Airports (LAWA) Chief Executive Officer Justin Erbacci, Goldman Sachs Chief Information Officer George Lee, Carlyle Group (CAG Holdings) Chief Strategy Officer Ginger Evans, Mississippi Governor Tate Reeves, Former Lieutenant Governor of Florida Carlos Lopez-Cantera, and Miami Mayor Francis Suarez. The event will also feature Gaurdie Banister, former President and CEO, Aera Energy LLC and Corporate Director of DOW, Russell Reynolds Associates, and Tyson Foods .
Each of these top speakers brings significant leadership experience managing some of the world’s largest and most iconic organizations, healthcare institutions and governments through the coronavirus pandemic and will cover topics related to global best practices to reopen economies, while most safely returning people to public spaces, offices, and campuses.
In addition to these top speakers, the two-day symposium will feature a former World Head of State , presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci , Virgin Group Founder Sir Richard Branson , and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta , as well as sessions with leading healthcare experts and government officials.
To attend the “COVID-19 R2R: The Road to Recovery” virtual leadership summit, please visit Everbridge’s event registration page .
“Everbridge provides key insights that public and private sector leaders need right now to navigate this next crucial phase of the coronavirus pandemic, to reopen economies while most safely returning people to public spaces, offices and campuses,” said Everbridge Chief Executive Officer David Meredith. “By leveraging our global partner and customer ecosystem, Everbridge continues to add top C-level leaders to our speaker lineup, as well as marquee keynotes including Dr. Anthony Fauci, Sir Richard Branson, Dr. Sanjay Gupta, and a former World Leader. While our most recent COVID-19 Symposium attracted well over 10,000 leaders across 150 countries, our current registrations remain on track to far exceed those numbers.”
The symposium will focus on the policies and actions organizations can take during the pandemic to keep people safe, execute contact tracing, return people to workplaces, campuses, and public spaces, protect supply chains, restore operations, and help organizations manage their reputations and communications to foster consumer safety and trust; all while managing across multiple critical events that could include hurricanes, wildfires, production stoppages, IT outages and cyberattacks.
To see a current list of speakers and register for the event, please visit here . Beyond the latest additions announced today, representative C-level speakers from Fortune 500 and international corporations also include a Fortune 25 Chief Executive Officer (CEO), Fortinet Founder, Chairman of the Board, and CEO Ken Xie, Accenture’s Arlin Pedrick, Auburn University’s President Jay Gogue, Aviva’s John Bernard, CAG Holdings’ Ginger Evans, Capital One’s William Baker, Fannie Mae’s Christopher Porter, Humana’s Stephan Pazienza, Lumen Technologies’ (formerly CenturyLink) Executive Vice President of Human Resources Scott Trezise, Optum’s Allison Miller, Rackspace Chief Legal and People Officer Holly Windham, and Siemens ’ Marco Mille, among others.
Speakers representing the healthcare and government sectors include Roberta Levy Schwartz, Ph.D., FACHE, Executive Vice President and Chief Innovation Officer at Houston Methodist and CEO of Houston Methodist Hospital ; Dr. Judy Monroe, Chief Executive Officer of the CDC Foundation ; Dr. Nancy Messonnier, Director of the Center for the National Center for Immunization and Respiratory Diseases (NCIRD ); Matt Roman, Chief Digital Strategy Officer of Duke University Health System ; Curt Wood, Chief Information Officer of the Commonwealth of Massachusetts ; Rebecca Baudendistel, Director of Public Warning at New York City Emergency Management Department ; Víðir Reynisson, Chief Superintendent of the Office of National Commission of Police in Iceland ; Benoît Vivier, European Union institutions liaison at the European Emergency Number Association (EENA) ; and Michael Hallowes, former National Director of Australia’s Emergency Alert program and Managing Director of Zefonar .
Over 5,300 global organizations use Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforce, rapidly communicate warnings, and protect supply chains. At the onset of the pandemic, Everbridge rapidly launched its COVID-19 Shield™ Return to Work and Contact Tracing software solutions followed by the introduction of Everbridge Control Center , the industry’s first off-the-shelf physical security information management software platform to help organizations return to work while complying with social distancing and Personal Protective Equipment (PPE) policies. Since the pandemic began, Everbridge customers have used its software to send more than 780 million coronavirus-related communications with vital information and instructions to safeguard their populations, employees, patients, and students.
Everbridge serves over 3,700 first responder agencies and 1,500 healthcare entities including the top pharmaceutical, biomedical and medical device and manufacturing companies, as well as the largest healthcare systems (overseeing more than 25 percent of all hospital beds in the U.S.), managed care organizations, pharmacies, and statewide health alert networks (HANs), including the CDC and the NIH.
The Everbridge Platform reaches over 600 million people and currently supports the countrywide public warning system deployments in all major regions of the world . Everbridge supports population-wide alerting in 11 countries across Europe, Asia, Oceania, The Middle East, Africa, and South America including Australia , Iceland , the Netherlands, New Zealand, Norway , Peru , Singapore and Sweden . Everbridge’s population alerting capabilities also power the entire states of California , Massachusetts , Vermont , New York , Connecticut , and Florida , as well as municipalities, counties and cities within 49 of the 50 United States, within all of Canada’s provinces, and throughout Europe and Asia, including deployments within multiple populous states in India .
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 14 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
